Item Details

18 Nov 2026

Viatris completes acquisition of Pacira BioSciences

Viatris has completed its acquisition of Pacira BioSciences, bringing the US non opioid pain management business into its innovative medicines division. Viatris offered $36.50 per share in cash, with approximately 66% of Pacira shares tendered before completion. HPC could identify specialist pharmaceutical businesses, medical technology suppliers and healthcare companies seeking strategic buyers.

Get in Touch

We’ll get back to you shortly.